Handelsavisen
prelaunch
Companies ›Healthcare ›VIH.BK
VI
VIH.BK — SET (Bangkok) Healthcare Facilities & Services

Srivichai vejvivat PCL

$8,85
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
4,68 %
Op margin
17,9 %
ROE
11,3 %
Net margin
14,2 %
Debt / equity
0,02
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Srivichai Vejvivat PCL provides healthcare services and equipment, primarily operating in the biotechnology sector.

Business. Srivichai Vejvivat PCL (VIH.BK) is a healthcare company engaged in healthcare facilities and services, with activities in biotechnology. The firm is headquartered in Thailand and is primarily listed on the Stock Exchange of Thailand (SET). Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
11,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning VIH.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to VIH.BK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Srivichai Vejvivat PCL (VIH.BK) is a healthcare company engaged in healthcare facilities and services, with activities in biotechnology. The firm is headquartered in Thailand and is primarily listed on the Stock Exchange of Thailand (SET). Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    Srivichai Vejvivat PCL maintains a strong capital structure with a low debt-to-equity ratio of 0.02, indicating minimal reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 4.64, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints.

    In terms of profitability, the company's return on equity (ROE) is 11.26%, and its return on assets (ROA) is 9.74%. These figures suggest that the company is generating solid returns relative to its equity and asset base, which is a positive indicator for investors. The operating margin, calculated as operating income divided by revenue, is 17.9%, indicating efficient cost management and strong operational performance.

    The company's revenue is primarily concentrated in its core healthcare services and biotechnology segments, with no significant geographic diversification reported in the available data. This concentration may expose the company to specific market risks, particularly in the healthcare sector, which is subject to regulatory and economic fluctuations.

    Looking ahead, the company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current and next fiscal years. The company's capital expenditure of -194.07 million THB indicates a reduction in investment in physical assets, which could be a strategic move to preserve cash or a sign of reduced expansion plans.

    The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified in the available data. However, the negative net cash position after subtracting total debt is a key risk flag that investors should monitor. The company's financial flexibility and ability to meet short-term obligations are supported by its strong equity base and low debt levels.

    Recent events and filings do not indicate any major operational or financial disruptions for Srivichai Vejvivat PCL. The company's financial performance and strategic direction appear to be stable, with no significant changes in its business model or market position reported in the latest available data.

    Key takeaways
    • Srivichai Vejvivat PCL has a strong equity base and low debt levels, contributing to a stable capital structure.
    • The company's ROE and ROA are above average, indicating efficient use of capital and assets.
    • Revenue is concentrated in the healthcare services and biotechnology segments, with no significant geographic diversification.
    • The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted.
    • The company's liquidity position is medium, with a current ratio of 4.64, but a negative net cash position after subtracting total debt is a key risk flag.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $8,85
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $3.87B
    Net cashⓘ
    -$67.5M
    Current ratioⓘ
    4.6
    Debt / equityⓘ
    0.0
    ROAⓘ
    9.7%
    ROEⓘ
    11.3%
    Cash conversionⓘ
    118.0%
    CapEx / revenueⓘ
    -6.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin17,9 %Above P75
    Net Margin14,2 %Above P75
    ROE11,3 %Above median
    Capex / Rev-6,3 %Above median
    D/E0,02Above P75
    Cash Conv1,18Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Srivichai vejvivat PCL Market data — financials · 2026-05-29

    Ownership & reference

    Leadership

    • Vichai VanadurongwanExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    VIH.BKCanonical
    SET (Bangkok) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage